$NPLS
NP Life Sciences Health Industry Group Inc.

2022 Q4 Form 10-Q Financial Statement

#000149315222032048 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $46.02K $41.00K $0.00
YoY Change 31.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $29.42K $20.83K
YoY Change 981.62%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $29.42K $20.83K
YoY Change 981.62%
Operating Profit -$5.440K -$20.83K
YoY Change -73.89%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.00
YoY Change
Pretax Income $16.60K -$5.440K -$20.83K
YoY Change -48.56% -73.88%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $16.60K -$5.440K -$20.83K
YoY Change -48.56% -73.88%
Net Earnings / Revenue 36.07% -13.27%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$484.90
COMMON SHARES
Basic Shares Outstanding 42.96M shares 42.96M shares 42.96M shares
Diluted Shares Outstanding 42.96M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $121.9K $25.01K
YoY Change 335.37%
Cash & Equivalents $121.9K $6.951K $25.01K
Short-Term Investments
Other Short-Term Assets $5.930K
YoY Change -43.14%
Inventory
Prepaid Expenses $5.925K $9.993K
Receivables
Other Receivables
Total Short-Term Assets $127.8K $25.01K
YoY Change 232.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00 $0.00
YoY Change 300.0%
TOTAL ASSETS
Total Short-Term Assets $127.8K $25.01K
Total Long-Term Assets $4.00 $0.00
Total Assets $127.8K $16.94K $25.01K
YoY Change 232.68% -32.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.130K $9.226K
YoY Change
Accrued Expenses $2.739K $5.000K $19.11K
YoY Change 1046.03% -73.84%
Deferred Revenue $99.60K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $108.5K $19.11K
YoY Change 45095.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $108.5K $19.11K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $108.5K $14.23K $19.11K
YoY Change 45284.1% -25.56%
SHAREHOLDERS EQUITY
Retained Earnings -$345.3K -$361.9K
YoY Change 5.78%
Common Stock $4.296K $4.296K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.32K $2.718K $5.900K
YoY Change
Total Liabilities & Shareholders Equity $127.8K $16.94K $25.01K
YoY Change 232.68% -32.25%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $16.60K -$5.440K -$20.83K
YoY Change -48.56% -73.88%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities $93.87K -$15.72K
YoY Change 3060.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities 93.87K -15.72K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash 93.87K -15.72K
YoY Change 3060.61%
FREE CASH FLOW
Cash From Operating Activities $93.87K -$15.72K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001781726
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56140
dei Entity Registrant Name
EntityRegistrantName
NP Life Sciences Health Industry Group Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2912878
dei Entity Address Address Line1
EntityAddressAddressLine1
4125 Blackhawk Plaza Circle
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 166
dei Entity Address City Or Town
EntityAddressCityOrTown
Danville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94506
dei City Area Code
CityAreaCode
(925)
dei Local Phone Number
LocalPhoneNumber
362-3169
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
GJCU
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42959574 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6951 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27986 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9993 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10425 usd
CY2022Q3 us-gaap Assets
Assets
16944 usd
CY2021Q4 us-gaap Assets
Assets
38411 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9226 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
239 usd
CY2022Q3 us-gaap Liabilities
Liabilities
14226 usd
CY2021Q4 us-gaap Liabilities
Liabilities
239 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42959574 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42959574 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42959574 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42959574 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4296 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4296 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
360330 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
360330 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-361908 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326454 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2718 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38172 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16944 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38411 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55982 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
91437 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
97950 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46440 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20834 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-35455 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-97950 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5440 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20834 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35455 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-97950 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5440 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20834 usd
us-gaap Interest Income Other
InterestIncomeOther
1 usd
us-gaap Interest Income Other
InterestIncomeOther
4 usd
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
1 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1 usd
us-gaap Net Income Loss
NetIncomeLoss
-35454 usd
us-gaap Net Income Loss
NetIncomeLoss
-97946 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5440 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20834 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-35454 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-97946 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5440 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20834 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
103849 usd
us-gaap Net Income Loss
NetIncomeLoss
-97946 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
5903 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38172 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38172 usd
us-gaap Net Income Loss
NetIncomeLoss
-35454 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2718 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2718 usd
us-gaap Net Income Loss
NetIncomeLoss
-35454 usd
us-gaap Net Income Loss
NetIncomeLoss
-97946 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-432 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9226 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4761 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4345 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21035 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93601 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21035 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-93601 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27986 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118611 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6951 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25010 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_802_eus-gaap--NatureOfOperations_zN3KY1OpURAi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_z9dBg1BUYLyc">NATURE OF OPERATIONS</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 33.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NP Life Sciences Health Industry Group Inc. (the “Company”) is a for profit corporation established under the corporation laws in the State of Nevada, United States of America on December 20, 2018. The Company was originally incorporated as “Guojiang Cultural Industry US, Inc.” and amended the name to “GJ Culture Group US, Inc.” on February 20, 2019. On September 8, 2022, the Company filed a Certificate of Amendment to its Articles of Incorporation with the State of Nevada to reflect its corporate name change from “GJ Culture Group US, Inc.” to “NP Life Sciences Health Industry Group Inc.”. The name change was effective as of the filing of the Certificate of Amendment with the State of Nevada. The Company is awaiting the approval of FINRA for the market effectiveness of the name change. Unless the context otherwise requires, all references to “NP Life Sciences Health Industry Group Inc.,” “GJ Culture Group US, Inc.,” “we,” “us,” “our” or the “Company” are to NP Life Sciences Health Industry Group Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is dedicated to providing educational services based on classical Chinese studies and culture. The Company’s goal is to serve as cultural and educational meeting point between China and the U.S. The Company intends to pursue its business objective by providing education and training courses based on classical Chinese studies, organizing China-U.S. international study tour activities for participants of all ages, as well as organizing and promoting China-U.S. cultural events, art fairs, exhibitions, and other activities promoting Chinese culture.</span></p>
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-361908 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21035 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_ztyANYVF1m6c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z9yrCKRF0urc">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the limited level of operations, the Company has not needed to make material assumptions or estimates other than the assumption that the Company is a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Income Loss
NetIncomeLoss
-35454 usd
us-gaap Net Income Loss
NetIncomeLoss
-97946 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42959574 shares
CY2022Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
361908 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
326454 usd

Files In Submission

Name View Source Status
0001493152-22-032048-index-headers.html Edgar Link pending
0001493152-22-032048-index.html Edgar Link pending
0001493152-22-032048.txt Edgar Link pending
0001493152-22-032048-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gjcu-20220930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
gjcu-20220930_cal.xml Edgar Link unprocessable
gjcu-20220930_def.xml Edgar Link unprocessable
gjcu-20220930_lab.xml Edgar Link unprocessable
gjcu-20220930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending